Targeted Chemotherapy Delivery Platform

Alpha Cancer Technologies Inc. (ACT) is advancing its targeted chemotherapy delivery platform based on Alpha FetoProtein (AFP) to enhance the performance of chemotherapy at lower dose with better safety.

AFP combined with chemotherapy targets cancer cells with a very high degree of selectivity. It has been shown to overcome drug resistance that many cancers develop in response to chemotherapy. This approach is highly selective for cancer cells that have AFP receptors (ovarian, lung, colon, gastric, liver, pancreatic cancers, leukemia, breast and more) and not cause damage to normal cells thus reducing systemic toxicity.

News

Articles

Downloads

Stay Informed


Contact Us

Dr. I. Sherman, CEO
Email: isherman@alpha-cancer.com
Phone: 416-826-6626
Fax: 416-782-3944

Richard Potts, Chairman
Email: rpotts@alpha-cancer.com
Phone: 416-464-2768
Fax: 416-946-1515

Address

Alpha Cancer Technologies
MaRS Center, South Tower
200-101 College St.
Toronto, Ontario, Canada
M5G 1L7